References
[1] Elkelany OO, Karaisz FG, Davies B, Krishna SG. An Overview of Pancreatic Neuroendocrine Tumors and an Update on Endoscopic Techniques for Their Management. Curr Oncol. 2023;30:7566-7580.
[2] Hallet J, Law CH, Cukier M, et al. Exploring the rising incidence of neuroendocrine tumors: a population-based analysis of epi-demiology, metastatic presentation, and outcomes. Cancer. 2015;121:589-597.
[3] Sonbol MB, Mazza GL, Mi L, et al. Survival and Incidence Patterns of Pancreatic Neuroendocrine Tumors Over the Last 2 Decades: A SEER Database Analysis. Oncologist. 2022;27:573-578.
[4] Pezzilli R, Partelli S, Cannizzaro R, et al. Ki-67 prognostic and therapeutic decision driven marker for pancreatic neuroendocrine neoplasms (PNENs): A systematic review. Adv Med Sci. 2016;61:147-153.
[5] Uccella S. Molecular Classification of Gastrointestinal and Pancreatic Neuroendocrine Neoplasms: Are We Ready for That? Endocr Pathol. 2024;35:91-106.
[6] Rindi G, Mete O, Uccella S, et al. Overview of the 2022 WHO Classification of Neuroendocrine Neoplasms. EndocrPathol. 2022;33:115-154.
[7] Maharjan CK, Ear PH, Tran CG, et al. Pancreatic Neuroendocrine Tumors: Molecular Mechanisms and Therapeutic Targets. Cancers. 2021;13:5117.
[8] Uccella S, La Rosa S, Metovic J, et al. Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites. Endocr Pathol. 2021;32:192-210.
[9] Perry RR, Feliberti EC, Hughes MS. Management of Pancreatic Neuroendocrine Tumors: Surgical Strategies and Controversies. Endocr Pract. 2024;30:908-916.
[10] Sulciner ML, Clancy TE. Surgical Management of Pancreatic Neuroendocrine Tumors. Cancers. 2023;15:2006.
[11] Mou Y, Wang ZY, Tan CL, et al. The role of primary tumor resection in patients with pancreatic neuroendocrine tumors with liver metastases. Front Oncol. 2022;12:838103.
[12] Chawla A, Williams RT, Sich N, et al. Pancreaticoduodenectomy and metastasectomy for metastatic pancreatic neuroendocrine tumors. J Surg Oncol. 2018;118:983-990.
[13] Cloyd JM, Omichi K, Mizuno T, et al. Preoperative fluorouracil, doxorubicin, and streptozotocin for the treatment of pancreatic neuroendocrine liver metastases. Ann Surg Oncol. 2018;25:1709-1715.
[14] Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011;364:501-513.
[15] Strosberg JR, Mizuno N, Doi T, et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results from the Phase II KEYNOTE-158 Study. Clin Cancer Res. 2020;26:2124-2130.
[16] Greenberg J, Limberg J, Verma A, et al. Metastatic pancreatic neuroendocrine tumors feature elevated T cell infiltration. JCI Insight. 2022;7:e160130.
[17] Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. Genome Biol. 2014;15:550.
[18] Perl AK, Wilgenbus P, Dahl U, et al. A causal role for E-cadherin in the transition from adenoma to carcinoma. Nature. 1998;392:190-193.
[19] Borowiec M, Liew CW, Thompson R, et al. Mutations at the BLK locus linked to maturity onset diabetes of the young and beta-cell dysfunction. Proc Natl Acad Sci USA. 2009;106:14460-14465.
[20] Esteghamat F, Broughton JS, Smith E, et al. CELA2A mutations predispose to early-onset atherosclerosis and metabolic syndrome and affect plasma insulin and platelet activation. Nat Genet. 2019;51:1233-1243.
[21] Sosa-Pineda B, Chowdhury K, Torres M, et al. The Pax4 gene is essential for differentiation of insulin-producing β cells in the mammalian pancreas. Nature. 1997;386:399-402.
[22] Sadanandam A, Wullschleger S, Lyssiotis CA, et al. A Cross-Species Analysis in Pancreatic Neuroendocrine Tumors Reveals Molecular Subtypes with Distinctive Clinical, Metastatic, Developmental, and Metabolic Characteristics. Cancer Discov. 2015;5:1296-1313.
[23] de Thé H. Differentiation therapy revisited. Nature Reviews Cancer. 2018;18:117-127.
[24] Zhu K, Xia Y, Tian X, et al. Characterization and therapeutic perspectives of differentiation-inducing therapy in malignant tumors. Front Genet. 2023;14:1271381.
[25] Lavudi K, Nuguri SM, Olverson Z, et al. Targeting the retinoic acid signaling pathway as a modern precision therapy against cancers. Front Cell Dev Biol. 2023;11:1254612.
[26] Maden M. Retinoic acid in the development, regeneration and maintenance of the nervous system. Nat Rev Neurosci. 2007;8:755-765.
[27] Clark JN, Whiting A, McCaffery P. Retinoic acid receptor-targeted drugs in neurodegenerative disease. Expert Opinion on Drug Metabolism & Toxicology. 2020;16:1097-1108.
[28] Shukla S, Tekwani BL. Histone Deacetylases Inhibitors in Neurodegenerative Diseases, Neuroprotection and Neuronal Differentiation. Front Pharmacol. 2020;11:537.
[29] Smith D, Lepage C, Vicaut E, et al. Observational Study in a Real-World Setting of Targeted Therapy in the Systemic Treatment of Progressive Unresectable or Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors (pNETs) in France: OPALINE Study. Adv Ther. 2022;39:2731-2748.
[30] Papaetis GS, Syrigos KN. Sunitinib: a multitargeted receptor tyrosine kinase inhibitor in the era of molecular cancer therapies. BioDrugs. 2009;23:377-389.